• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Biotronik claims Orsiro stent beats Abbott’s Xience in heart attack subgroup

Biotronik claims Orsiro stent beats Abbott’s Xience in heart attack subgroup

February 18, 2016 By Brad Perriello

Biotronik's Orsiro stentBiotronik today touted study results showing that its hybrid Orsiro drug-eluting stent may have the edge on the Xience Prime and Xience Xpedition stents made by Abbott (NYSE:ABT) in patients with a certain kind of heart attack.*

Published in the journal EuroIntervention, a sub-analysis from the Bioscience trial of 407 patients with ST-segment elevation myocardial infarctions showed that the rate of target lesion failure after a year was 3.3% for the Orsiro-treated population and 8.7% in the Xience group.

“With these extremely promising results for the Bioscience trial’s STEMI patients in hand, it is now time to demonstrate Orsiro’s far-reaching capabilities with a much larger randomized, controlled trial specifically focused on this indication,” Biotronik vascular intervention marketing VP  Alexander Uhl said in prepared remarks. “In an effort to shed light on the superb efficacy of Orsiro in this challenging patient population, we expect to begin enrolling patients to the BioSTEMI trial soon.”

“During the Bioscience trial, Orsiro was associated with a significantly reduced risk of the primary endpoint of TLF for STEMI patients,” added lead author Dr. Thomas Pilgrim of Bern, Switzerland’s University Clinic for Cardiology. “We hypothesize this is due to Orsiro’s bioabsorbable polymer, which might provide favorable results on arterial healing after implantation. The effect of an enhanced healing response may be more pronounced in the inflammatory milieu of STEMI. As we currently have only limited data available on the clinical performance of newer generation DES in STEMI patients, we will soon attempt to extend these results in a dedicated randomized trial known as BioSTEMI.”

*Correction, Feb. 22, 2016: This article originally referred to the Xience devices as being made by Boston Scientific. We regret the error. Return to the corrected sentence.

Filed Under: Cardiovascular, Clinical Trials, Stents Tagged With: Biotronik, Boston Scientific

More recent news

  • Vicarious Surgical inks surgical robot collab with hospital, eyes first clinical patients
  • Bioliberty launches hub for soft-robotic wearable devices
  • Zynex submits laser pulse oximeter to FDA
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub
  • Product liability lawsuits target Medtronic, Boston Scientific spinal cord stim tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy